Home > Journals > Minerva Pneumologica > Past Issues > Minerva Pneumologica 2000 March;39(1) > Minerva Pneumologica 2000 March;39(1):1

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

ORIGINAL ARTICLES   

Minerva Pneumologica 2000 March;39(1):1

Copyright © 2000 EDIZIONI MINERVA MEDICA

language: Italian

Therapeutic action of lomefloxacin. Microbiological and clinical evaluation in cases of infective re-exacerbation of chronic bronchitis

Zannini G., Masotti A., Bottrighi P., Rossi A., Rossi M., Settino A., Ferrari P.


PDF


Background. Patients suffering from chronic bronchitis experience periodic episodes of infective re-exacerbation. This study compared the microbiological and clinical efficacy of lomefloxacin vs ciprofloxacin in antibiotic treatment of the re-exacerbation of chronic bronchitis.
Methods. The study involved 5 Centres of Pneumology and used a randomised prospective open experimental design, comparing lomefloxacin (Group L) 400 mg/die and ciprofloxacin (Group C) 500 mg x 2/die, duration of treatment 7-10 days, follow-up of up to one month after treatment. The patients enrolled in the study met the following criteria: clinical signs of the re-exacerbation of chronic bronchitis and microbiological identification of the pathogen. Clinical and microbiological parameters were evaluated at the following stages: before treatment, 3-4 days during treatment, at the end of treatment and one month after treatment.
Results. A complete or partial resolution of signs and symptoms was observed at the end of treatment in 93% of Group L and 90% of Group C, with eradication of the pathogen isolated on enrolment in 73% of Group L and 72% of Group C.
Conclusions. Both antibiotics were equally efficient in resolving the clinical picture and eradicating the pathogens responsible for the re-exacerbation of chronic bronchitis. No collateral effects were noted in relation to the treatment. A single dose of lomefloxacin may improve compliance in elderly patients who are often receiving concomitant chronic treatment.

top of page